SEC Comment Letter 0000000000-25-001979 to TuHURA Biosciences, Inc./NV (HURA)
TuHURA Biosciences, Inc./NV
Date: Feb. 20, 2025 · CIK: 0001498382 · Accession: 0000000000-25-001979
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284787
Letter
February 20, 2025 James Bianco Chief Executive Officer TuHURA Biosciences, Inc. 10500 University Center Dr., Suite 110 Tampa, FL 33612 Re:TuHURA Biosciences, Inc. Registration Statement on Form S-4 Filed February 7, 2025 File No. 333-284787 Dear James Bianco: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-4 General 1.We note that your proxy statement/prospectus includes your annual and interim financial statements, as well as annual and interim financial statements for Kintara Therapeutics, Inc. and Kineta, Inc. However, we note that the proxy statement/prospectus only includes a management's discussion and analysis for the periods covered by your interim financial statements and Kineta's interim financial statements. Please revise your proxy statement/prospectus to include a management's discussion and analysis covering all the periods covered by the financial statements included in the proxy statement/prospectus. Refer to Item 303(b) of Regulation S-K and Instruction 1 thereto.
February 20, 2025 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Jessica Dickerson at 202-551-8013 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Curt P. Creely, Esq.
Show Raw Text
February 20, 2025
James Bianco
Chief Executive Officer
TuHURA Biosciences, Inc.
10500 University Center Dr., Suite 110
Tampa, FL 33612
Re:TuHURA Biosciences, Inc.
Registration Statement on Form S-4
Filed February 7, 2025
File No. 333-284787
Dear James Bianco:
We have conducted a limited review of your registration statement and have the
following comment.
Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments.
Registration Statement on Form S-4
General
1.We note that your proxy statement/prospectus includes your annual and interim
financial statements, as well as annual and interim financial statements for Kintara
Therapeutics, Inc. and Kineta, Inc. However, we note that the proxy
statement/prospectus only includes a management's discussion and analysis for the
periods covered by your interim financial statements and Kineta's interim financial
statements. Please revise your proxy statement/prospectus to include a management's
discussion and analysis covering all the periods covered by the financial statements
included in the proxy statement/prospectus. Refer to Item 303(b) of Regulation S-K
and Instruction 1 thereto.
February 20, 2025
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Jessica Dickerson at 202-551-8013 or Joe McCann at 202-551-6262
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Curt P. Creely, Esq.